Compare Pfizer Inc (PFE) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Schwab US Dividend Equity ETF — how do they compare? Pfizer Inc trades at $27.93 (market cap $158.56B), while Schwab US Dividend Equity ETF trades at $33.01 (market cap $110.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.18% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| PFE | SCHD | |
|---|---|---|
Market Cap | $158.56B | $110.56B |
Volume | 44,138,282 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $35.21 |
52-Week Low | $23.67 | $26.44 |
Typical Hold Time | 158 Days | 62 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SCHD trades at $32.65, down 0.61% with a bearish technical signal from moving averages. Recent news highlights its strong 2026 performance against the S&P 500 and a recent dividend declaration. The ETF's defensive dividend strategy faces pressure from rising interest rates, contributing to recent price weakness from August highs near $35.
The outlook balances income growth potential against interest rate sensitivity. Near-term support at $32 provides a key level to watch, while the dividend-focused approach offers stability for long-term investors despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
